Avacta Group Plc operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Avacta Group Plc with three other
companies in this sector in UNITED KINGDOM :
Fusion Antibodies PLC
(2019
sales of £2.18 million [US$3.04 million]
),
Redx Pharma PLC
(£3.13 million [US$4.37 million]
of which 100%
was pharmaceutical), and
Open Orphan PLC
(£3.84 million [US$5.36 million]
of which 100%
was Consulting and Clinical trail services).
Sales Analysis.
Avacta Group Plc reported sales of £3.89 million (US$5.43 million)
for the
year ending
December of 2019.
This
represents
an
increase of 40.8%
versus 2018, when the company's sales were £2.76 million.
This was the fourth straight year of sales growth at Avacta Group Plc.
Sales of Life Sciences saw an increase
that was more than double the company's growth rate: sales were up
96.7% in 2019, from
£1.19 million to £2.35 million.
Not all segments of Avacta Group Plc experienced an increase in sales in 2019:
sales of Animal Health fell 1.7% to £1.54 million.